BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

July 21, 2014 updated by: Boehringer Ingelheim

A Phase II Single-arm Trial of BIBW 2992 in EGFR FISH Positive Non-small Cell Lung Cancer Patients

The primary objective of this open-label, single arm Phase II trial is to explore the efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by the RECIST criteria in patients with EGFR FISH positive advanced NSCLC Stage IIIB or IV, selected according to the following scheme:

  • Forty (40) 1st line patients
  • Thirty (30) 2nd line patients Patients entered into the trial will be treated and followed until death or lost to follow-up. Additional information will be obtained on the safety profile and PK analysis of BIBW 2992.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Arezzo, Italy
        • 1200.40.39011 Boehringer Ingelheim Investigational Site
      • Aviano (PN), Italy
        • 1200.40.39007 Boehringer Ingelheim Investigational Site
      • Faenza (RA), Italy
        • 1200.40.39013 Boehringer Ingelheim Investigational Site
      • Genova, Italy
        • 1200.40.39003 Boehringer Ingelheim Investigational Site
      • Livorno, Italy
        • 1200.40.39010 Boehringer Ingelheim Investigational Site
      • Lugo (RA), Italy
        • 1200.40.39012 Boehringer Ingelheim Investigational Site
      • Modena, Italy
        • 1200.40.39008 Boehringer Ingelheim Investigational Site
      • Monza (MI), Italy
        • 1200.40.39005 Boehringer Ingelheim Investigational Site
      • Padova, Italy
        • 1200.40.39006 Boehringer Ingelheim Investigational Site
      • Perugia, Italy
        • 1200.40.39002 Boehringer Ingelheim Investigational Site
      • Prato, Italy
        • 1200.40.39004 Boehringer Ingelheim Investigational Site
      • Ravenna, Italy
        • 1200.40.39009 Boehringer Ingelheim Investigational Site
      • Rozzano (MI), Italy
        • 1200.40.39001 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  1. Male and female patients aged >18 years.
  2. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural effusion) or Stage IV and histopathological classification of adeno- or bronchoalveolar carcinoma (BAC).
  3. Increased EGFR gene copy number assessed by FISH analysis. After signed informed consent, positive result to EGFR FISH determination is mandatory to proceed to other screening assessments.
  4. At least one tumour lesion that can accurately be measured by computed tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with longest diameter to be recorded as more or same 20 mm using conventional techniques or moro or same 10 mm with spiral CT scan.
  5. Patients not previously exposed to chemotherapy for NSCLC (1st line patients, 40 in total; for these subjects adjuvant chemotherapy is allowed if at least 12 months elapsed since last course of treatment), or patients with relapse after one systemic treatment (2nd line patients, 30 in total; if less than 12 months elapsed since adjuvant chemotherapy, patients are 2nd line ones, as adjuvant chemotherapy must be considered a line of treatment).
  6. Life expectancy of at least three (3) months.
  7. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0, 1 or 2.
  8. Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion criteria:

  1. More than two (2) prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic NSCLC, included adjuvant chemotherapy if relapse occurred less than 12 months before
  2. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR inhibiting small molecule or antibody.
  3. Active brain metastases (stable <4 weeks, symptomatic, requiring treatment with anticonvulsants, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least one month before randomization.
  4. Chemo-, hormone- (other than megestrol acetate or steroids required for maintenance non-cancer therapy) or immunotherapy within the past 4 weeks before first drug administration.
  5. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn disease, malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline
  6. Patients who have any other life-threatening illness or organ system dysfunction which, in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
  7. Other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer and in situ cervical cancer).
  8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.
  9. Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents).
  10. Patients with known HIV, active hepatitis B or active hepatitis C.
  11. Known or suspected active drug or alcohol abuse.
  12. Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial.
  13. Pregnancy or breast feeding.
  14. Patients unable to comply with the protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BIBW 2992
BIBW 2992 in EGFR FISH positive NSCLC patients
Drug: BiBW 2992
BIBW 2992 in EGFR FISH positive NSCLC patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Best Objective Response
Time Frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.
Percentage of participants with best objective response: confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0.
Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Objective Response (OR) Categorized by Time
Time Frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.
Cumulative number of participants with objective response by time points with responders.
Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.
Duration of Confirmed Objective Response (OR)
Time Frame: Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.
Duration of confirmed Objective Response is measured from the time of first Objective Response (OR) to the time of progression or death (or date of censoring for progression free survival).
Tumour assessments were performed at baseline (tumour assessment obtained within 4 weeks prior to beginning of treatment), week 8, and every 8 weeks until last response assessment 28NOV12.
Percentage of Participants With Disease Control (DC)
Time Frame: Every 8 weeks until last response assessment 28NOV12
Percentage of participants with Objective response (OR) or stable disease (SD) as determined by RECIST version 1.0.
Every 8 weeks until last response assessment 28NOV12
Duration of Confirmed Disease Control
Time Frame: Every 8 weeks until last response assessment 28NOV12
Duration of Disease Control is measured from the time of first Objective Response to the time of progression or death (or date of censoring for progression free survival) or respectively for SD as the time from date of randomization to date that disease progression.
Every 8 weeks until last response assessment 28NOV12
Progression Free Survival (PFS) Time
Time Frame: Every 8 weeks until last response assessment 28NOV12
Progression Free Survival time defined as time from the start of treatment to the earliest of progression (RECIST), clinical progression (investigator), start of new anti-cancer treatment or death.
Every 8 weeks until last response assessment 28NOV12
Overall Survival (OS) Time
Time Frame: Baseline until last vital status assessment 17JUN13
Overall survival time is defined as time from the date of start of treatment to the date of death.
Baseline until last vital status assessment 17JUN13
Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15)
Time Frame: Day 15
Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15.
Day 15
Number of Participants With Clinical Relevant Finding in Gastrointestinal and Skin Disorder
Time Frame: First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks
The safety of patients was overall assessed in terms of adverse events (AEs), graded according to US NCI CTCAE version 3.0 [R04-0474], including skin reactions and gastrointestinal AEs.
First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks
Number of Participants With Clinical Relevant Findings in Laboratory Safety Parameters, Vital Signs and Left Ventricular Ejection Fraction
Time Frame: First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks

Number of participants with clinical relevant findings in Laboratory safety parameters, vital signs and Left ventricular ejection fraction . Relevant findings or worsenings of baseline conditions were reported as Adverse Events.

There were no clinically relevant finding reported for Vital signs and Left ventricular ejection fraction (LVEF).
First administration of trial medication until 28 days after last administration of trial medication, up until 194 weeks
Assessment of Eastern Cooperative Oncology Group (ECOG) Performance Status
Time Frame: End Of Treatment, up until 190 weeks

Performance status assessed according to Eastern Cooperative Oncology Group (ECOG) performance status based on categories defined below :

0 : Fully active, able to carry on all pre-disease performance without restriction.

  1. : Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
  2. : Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
  3. : Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
  4. : Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
  5. : Dead.

Note: The ECOG scores presented are assessed at the end of treatment not at baseline, hence the patients having ECOGs>2 are included.
End Of Treatment, up until 190 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2008

Primary Completion (Actual)

May 1, 2012

Study Registration Dates

First Submitted

November 21, 2008

First Submitted That Met QC Criteria

November 21, 2008

First Posted (Estimate)

November 24, 2008

Study Record Updates

Last Update Posted (Estimate)

July 22, 2014

Last Update Submitted That Met QC Criteria

July 21, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1200.40
  • 2008-001264-37 (EudraCT Number: EudraCT)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Clinical Trials on BiBW 2992

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe